Regulated and Reversible Induction of Adult Human β-Cell Replication
Induction of proliferation in adult human β-cells is challenging. It can be accomplished by introduction of cell cycle molecules such as cyclin-dependent kinase 6 (cdk6) and cyclin D1, but their continuous overexpression raises oncogenic concerns. We attempted to mimic normal, transient, perinatal human β-cell proliferation by delivering these molecules in a regulated and reversible manner. Adult cadaveric islets were transduced with doxycycline (Dox)-inducible adenoviruses expressing cdk6 or cyclin D1. End points were cdk6/cyclin D1 expression and human β-cell proliferation, survival, and function. Increasing doses of Dox led to marked dose- and time-related increases in cdk6 and cyclin D1, accompanied by a 20-fold increase in β-cell proliferation. Notably, Dox withdrawal resulted in a reversal of both cdk6 and cyclin D1 expression as well as β-cell proliferation. Re-exposure to Dox reinduced both cdk/cyclin expression and proliferation. β-Cell function and survival were not adversely affected. The adenoviral tetracycline (tet)-on system has not been used previously to drive human β-cell proliferation. Human β-cells can be induced to proliferate or arrest in a regulated, reversible manner, temporally and quantitatively mimicking the transient perinatal physiological proliferation that occurs in human β-cells.
Human β-cell expansion, in vivo or ex vivo, is an important, but unachieved, goal of diabetes research. This concept drives active research programs in hES and iPS cell differentiation, xenograft sources of islets, expansion and survival of cadaveric human β-cells, and high-throughput small molecule screens, hoping to find approaches that could allow β-cell replacement therapy. Unfortunately, adult human β-cells have proven recalcitrant to induction of proliferation by growth factors, nutrient signaling pathways, and maneuvers such as partial pancreatectomy, induction of insulin resistance, pregnancy, and high-fat feeding (1–7), all of which induce remarkable rodent β-cell proliferation. Thus, investigators are left with replication-recalcitrant adult cadaveric islets as the major starting material for research in β-cell replacement.
We have shown that it is possible to drive adult human β-cells to replicate robustly, using in vitro and in vivo models, by delivery of cell cycle molecules such as cyclin-dependent kinase 6 (cdk6) and cyclin D1 (8–11). This allows retention of differentiated functions, such as glucose-stimulated insulin secretion, and has no apparent adverse effects on survival (8–11). A drawback of these studies is that they were performed using continuous overexpression of cdk6 and cyclin D1 driven by the constitutive cytomegalovirus (CMV) promoter in adenoviral vectors, raising concerns of oncogenic transformation over the long term.
Interestingly, several groups have shown that replication occurs perinatally in the embryonic and neonatal human pancreas for several months, albeit at relatively slow rates (12–14). These observations suggest that strategies that attempt to mimic normal transient perinatal human β-cell proliferation and expansion may have therapeutic application. Thus, in the current study, we asked if adult human β-cell proliferation could be activated in an inducible manner that might also allow restoration of cell cycle arrest (i.e., minimizing oncogenic risk) once a desired β-cell mass had been achieved, all using a temporal profile that resembles events in human pancreas development. Although both cdk6 and cyclin D1 are individually able to drive human β-cell replication in vitro (9,10), we selected the cdk6 and cyclin D1 combination for this study, among several cdk-cyclin pair options, because the combination produces greater proliferation than either alone, and because we had tested this combination in vivo in the streptozocin-diabetic NOD-severe combined immunodeficiency model (9,10).
RESEARCH DESIGN AND METHODS
Human islets were obtained from the National Institutes of Health (NIH)– and Juvenile Diabetes Research Foundation (JDRF)–supported Integrated Islet Distribution Program (IIDP) and Dr. Tatsuya Kin (Clinical Islet Laboratory, University of Alberta, Edmonton, Alberta, Canada). Adenovirus preparation, immunoblots, glucose-stimulated insulin secretion, cdk and cyclin expression studies, and proliferation and survival studies were performed as described in detail previously (8–11,15,16) and in the figure legends. Results are expressed as averages ± SEM. Statistical differences were determined by two-tailed, unpaired Student t test or by ANOVA for repeated measures with post hoc analysis, as indicated in the figure legends.
Cdk6 and cyclin D1 can be overexpressed in a dose-dependent manner in human β-cells transduced with tet-inducible adenoviruses.
Human islets were transduced with an adenovirus delivering the tet transactivator (Ad.TTA) and either a control adenovirus expressing green fluorescent protein (Ad.GFP) or adenoviruses expressing cdk6 or cyclin D1 under the control of the tet response element (Ad.TRE-cdk6 or Ad.TRE-cyclin D1). Increasing amounts of doxycycline (Dox) (0–1 μg/mL) were added to the medium to define the dose responsiveness of the cdk-6 and cyclin D1 expression. Figure 1 shows that cyclin D1 or cdk6, or both, markedly increased with rising concentrations of Dox, plateauing at 0.1 μg/mL Dox. Close examination indicates that both cdk6 and cyclin D1 were expressed at low levels in the absence of Dox. For example, control (Ad.GFP-transduced) islets expressed 12.2% of the maximal amount of cdk6 expressed by Ad.TRE-cdk6 (with 0.1 μg/mL Dox), whereas Ad.TRE-cdk6 without Dox exposure expressed 23% of the maximum; similarly, Ad.GFP-transduced islets and Ad.TRE-cyclin D1 without Dox expressed 2.7 and 13.9% of maximal cyclin D1 levels, respectively. This suggests some “leakiness” of the TRE promoter, but below levels associated with activation of proliferation (see below).
To determine the optimal time course for induction, human islets were transduced, placed in media containing 1 μg/mL Dox, and then harvested 24, 48, or 72 h later. Supplementary Fig. 1 demonstrates that both cell cycle proteins increase rapidly over 72 h. There was no further increase after 72 h (not shown).
Induction of human β-cell proliferation by Dox.
Using laser confocal microscopy on isolated dispersed islets on coverslips, we examined BrdU incorporation into insulin+ cells. In Fig. 2A, negative controls (Ad.TRE-cdk6 and Ad. RE-cyclin D1 without Dox, or Ad.GFP with Dox) did not show adenovirus-derived expression of cdk6 or cyclin D1 (no white hemagglutinin [HA] epitope tag staining). On the other hand, cdk6/cyclin D1 staining (white HA tag) was clearly induced by Dox in the right panels. Importantly, it is also clear that the adenoviruses were expressed in β-cells, because the white HA tag colocalizes in many green insulin+ cells. Most importantly, BrdU staining can be seen prominently in human β-cells expressing cdk6/cyclin D1. In the bottom right panels, the HA staining has been separated from the merged images to more clearly demonstrate the BrdU staining in insulin+ cells.
These experiments were repeated using 13 different human islet preparations and quantified, as shown in Fig. 2B. As can be seen, although very few insulin+ cells were proliferating (BrdU+) when transduced either with the Ad.GFP or with the Ad.TTA+Ad.TRE-cyclin D1/cdk6 in the absence of Dox, transduction of β-cells with Ad.TRE-cdk6/cyclin D1 in the presence of increasing amounts of Dox led to marked, dose-related increases in β-cell BrdU incorporation, ranging from 2.5 up to 10%. Thus, it is possible to activate adult human β-cell proliferation by the introduction of Dox in a dose-dependent manner. Importantly, glucose-stimulated insulin secretion was not adversely affected by induction of proliferation, and insulin and pdx1 mRNA expression also were not diminished (Supplementary Fig. 2).
Expression of cdk6 and cyclin D1 does not induce cell death of transduced human islets.
Transferase-mediated dUTP nick-end labeling (TUNEL) staining of transduced dispersed islets performed after 3 days of cdk6/cyclin D1 induction revealed no increase in the rare TUNEL-positive cells (Supplementary Fig. 3A and B). Cleaved caspase-9, a product of the intrinsic apoptotic pathway, was not significantly elevated in islets overexpressing cdk6 and cyclin D1. Similarly, cleaved caspase-3, activated in both the extrinsic and intrinsic pathways, independently confirmed that there was no increase in cell death, despite activation of cell cycle proliferation by cdk6/cyclin D1. Interleukin (IL)-1β treatment (100 units/mL) had no effect on TUNEL immunostaining in Ad.cdk6/cyclin D1–treated islets in the presence of Dox (mean ± SEM, 0.3 ± 0.31% of insulin-positive cells) vs. controls (Ad.GFP 1.4 ± 0.8%, or Ad.cdk6/cyclin D1 islets with no Dox 0.95 ± 0.94; P = NS, one-way ANOVA). Similarly, cell death as assessed using cleaved caspase-3 and -9 did not increase in response to IL-1β in cdk6/cyclin D1–expressing islets (not shown).
Removal of Dox results in normalization of cdk6/cyclin D1 expression and cessation of human islet proliferation.
To mimic normal developmental events, and to avoid oncogenic concerns, we explored whether, and how quickly, the induced cdk6/cyclin D1 might decline after Dox withdrawal. Six different human islet preparations were transduced with adenoviruses and incubated for 3 days in complete medium containing 1 μg/mL Dox, at which time they were washed with phosphate-buffered saline and tet-free medium was added. Islets were then either harvested immediately (referred to as “day 0”) or at day 7. Figure 3 shows that 1) in six human islet preps, cdk6 and cyclin D1 return to baseline levels observed in control-transduced human islets; and 2) when administered in combination (as well as when expressed individually as in Supplementary Fig. 4), they both return to baseline within 7 days of Dox withdrawal. Supplementary Fig. 4 further indicates, using an additional six human islet preparations, that 1) the decline in human islets is progressive over the course of 1 week, declining by 82 and 94%, respectively; and 2) the decline in cdk6 and cyclin D1 occurs with comparable timing whether administered in combination (as in Fig. 3) or individually (as in Supplementary Fig. 4).
We next queried whether it was possible to reverse the proliferative effect in human β-cells by withdrawing Dox. Figure 4A independently confirms results in Fig. 2, showing that expressing cdk6 and cyclin D1 in β-cells for 3 days leads to an increase in BrdU incorporation (top row). It further demonstrates that this proliferation continues for at least 10 days in the presence of Dox (second row). Significantly, 3 days of Dox exposure followed by a 7-day washout completely abolished the proliferation (BrdU immunostaining) in β-cells (third row). Proliferation in β-cells promptly resumed when Dox was reintroduced (bottom row). In Fig. 4B, the number of BrdU+ and insulin+ cells over time is quantified, confirming that 3 days of Dox induces robust proliferation, which disappears within 7 days of Dox withdrawal, and can be reinduced to the full prior extent by re-exposure to Dox for 3 days.
These studies converged on two principal goals. First, they sought to determine whether it is possible to reversibly activate, inactivate, and reactivate human β-cell replication. And second, they sought to do this in a way that mimics the temporal sequence of human fetal β-cell replication, with proliferation being activated for a period of a few weeks or months, with the β-cells then allowed to return to quiescence. The results make the novel points that it is indeed possible to inducibly and transiently activate adult human β-cell replication, to temporally mimic normal proliferative events in human fetal β-cells, and to do so in a way that might navigate away from oncogenic concerns, while also retaining β-cell function and survival.
We have shown that several members of the G1/S family of molecules, such as cdk6 and cyclin D1, are able to effectively drive adult human β-cell cycle progression (8–11). Notably, we have also shown that when transplanted into immunodeficient diabetic mice, cdk6- and cyclin D1–overexpressing human β-cells continue to proliferate for 6–8 weeks, and do so in a way that actually improves β-cell function/glycemic control (9,10). Although these prior studies are promising, they are also a cause for worry, because they used adenoviral transduction using the constitutive CMV promoter, which leads to sustained expression. This raises the realistic concern that sustained overexpression of cdks and cyclins, many of which are well-established oncogenes in other contexts, might lead to tumor formation in transplanted islets exposed to these agents.
The first current goal, developing a means of reversibly inducing, then reversing, then reactivating brisk human β-cell replication, was achieved. These findings make the point that it is indeed possible to reversibly activate as well as arrest human β-cell replication, events that provide hope that strategies to allay oncogenic concerns associated with sustained cell cycle activation may be feasible.
The second goal, mimicking the transient proliferation that occurs in normal human development, was also achieved. Dox was able to activate, its withdrawal inactivate, and its reintroduction reactivate adult human β-cell replication. The time span we used (3, 7, and 10 days) was briefer than that which occurs in normal development (weeks to months), but further extending proliferation with longer exposure to Dox is clearly possible, because we have already demonstrated that prolonged (2 months) induction of human β-cell replication is possible using these approaches (9,10,15). The proliferation rates herein were comparable to rates achieved by constitutive CMV promoter adenoviruses in prior studies (9,10). Significantly, we were also able to achieve rates of proliferation that are comparable to, or exceed, those observed in developing human pancreas (12–14). These observations support the notion that induction of human β-cell replication at the 5% range for 2–3 months may be sufficient to expand endogenous and ex vivo sources of human β-cells.
These studies also have limitations. One is that they use gene therapy techniques, and as such are unlikely to be directly acceptable for human diabetes therapy. Hence, they serve as proof-of-principle studies, demonstrating that therapeutic, reversible human β-cell expansion is possible, and provide additional impetus and targets for searches for small molecules, growth factors, nutrients, and signaling pathways that will drive expansion of adult human β-cells, whether they are derived from cadaveric or stem cell sources. Another limitation is that no in vivo transplant studies were performed. However, because those experiments are expensive and time consuming, and because we already have shown in two prior studies that transplant of human islets expressing cdk6 and cyclin D1 function superiorly as compared with control human islets (9,10), the incremental knowledge gained through such experiments would be marginal.
In summary, these studies demonstrate that it is technically feasible to induce robust adult human β-cell replication in a regulated manner and to reverse this replication, attenuating oncogenic concerns and mimicking the transient β-cell proliferation that normally occurs in the developing human pancreas. These studies document that with the expanding list of β-cell cycle targets, and small molecule screens that are in progress, regulated proliferation of adult human β-cells is a feasible goal.
This work was supported by the Beta Cell Biology Consortium through NIH grants U01-DK-072473 and U01-DK-089538. It was also supported by NIH Grant R01-DK-55023 and JDRF grants 1-2008-39 and 34-2008-630. Human islets were generously supplied by the National Institute of Diabetes and Digestive and Kidney Diseases– and JDRF-supported IIDP.
No potential conflicts of interest relevant to this article were reported.
Parts of this study were presented at the 70th Scientific Sessions of the American Diabetes Association, Orlando, Florida, 25–29 June 2010.
K.K.T. researched data, contributed to discussion, and wrote the manuscript. J.W.K. and F.G.S. researched data. N.M.F.-T. contributed to discussion. A.F.S. originated the initial idea, contributed to discussion, and wrote the manuscript. K.K.T. and A.F.S. are guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
The authors thank Drs. Donald K. Scott, Adolfo Garcia-Ocaña, Rupangi C. Vasavada, and Laura C. Alonso at the University of Pittsburgh School of Medicine for many helpful discussions during the preparation of these studies. The authors also particularly thank Dr. Tatsuya Kin.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0580/-/DC1.
- Received May 2, 2011.
- Accepted November 8, 2011.
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.